BFRG

BullFrog AID

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$0.85

Analysis reference price unavailable

Analysis 2026-09-04 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$0.40

Analysis reference price unavailable

Analysis 2026-09-04 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.18

Analysis reference price unavailable

Analysis 2026-09-04 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-04

AI commentary

This is a low-coverage, monitoring-style setup. The packet contains no recent news, social coverage, analyst targets or reliable post-filing market-reaction data. The Q2 revenue milestone and higher cash balance are constructive, but they are offset by continued going-concern language, equity dependence and the unresolved Nasdaq bid-price deficiency. Confidence remains limited despite strong filing evidence.

RankAlpha Sentiment Codex - 2026-09-04

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31catalystFurther financing and dilution remain likelyHigh impact

The June 2026 10-Q reported $6.9 million of cash, $3.2 million of operating cash use in the first half, approximately $2.0 million of ATM proceeds and $5.8 million of ELOC proceeds, while still stating that additional capital is required and substantial doubt about going-concern status remains [#10-Q-2026-08-14].

2027-02-08eventNasdaq bid-price compliance deadline remains a binary overhangHigh impact

Nasdaq granted BullFrog an additional compliance period through February 8, 2027 after the company failed to regain the $1.00 minimum bid-price requirement. Management indicated it intends to use a reverse split if the deficiency is not cured organically [#8-K-2026-08-20].

2027-03-31catalystMilestone follow-through from the pharmaceutical feasibility agreementHigh impact

BullFrog recognized $215,385 after completing the first deliverable under a one-year March 2026 feasibility agreement with a global pharmaceutical client. Additional milestones or an exclusive license option could provide operating validation, but the agreement remains early-stage and execution-dependent [#10-Q-2026-08-14].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-04 • Updated nightlySource: Internal modelMethodology